Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.
Key opportunities include capitalizing on rising screen time, increased demand for preservative-free & advanced formulations, ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy ...
Just The News on MSN
Pfizer's COVID antiviral, bankrolled by Biden administration, doesn't help high-risk adults: study
New England Journal of Medicine lets Anthony Fauci and his onetime deputy play down results in editorial alongside study from ...
The FDA announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials ...
Paying Patients to Access the Nation’s #1 Prescribed Oral Blood ThinnerPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Eliquis--The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) — (Pfizer NYSE: PFE) Alliance ...
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling efficacy and tolerability data for zovegalisib ...
Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...
Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 ...
Spring’s warmer weather lures people outdoors – and into possible contact with ticks that spread Lyme disease. Already, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results